+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
T

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining an interleukin-6 inhibitor called tocilizumab with endovascular therapy in adults who have experienced an acute posterior circulation large-vessel occlusion stroke. This phase III clinical trial aims to see if adding tocilizumab can improve recovery outcomes for these patients. The trial is randomized, double-blind, and placebo-controlled, ensuring a rigorous comparison between treatments. Participants will receive either endovascular treatment combined with a single intravenous infusion of 240 mg tocilizumab or endovascular treatment combined with a placebo infusion. The infusion will be given immediately after randomization within 30 minutes and will take more than one hour to complete. This study involves two groups running in parallel to compare the effects of tocilizumab against placebo. During the study, participants will be assessed on their recovery using the modified Rankin Scale at 90 days as the main measure. Additional assessments include neurological improvement shortly after treatment, stroke severity scores at 7 days, and quality of life evaluations up to one year. Safety and functional outcomes will be closely monitored through various scales and indexes, with the total follow-up lasting up to one year after treatment.

Age: 18Years +All GendersPhase 3
30 locations
I

Actively Recruiting

Researchers are conducting a multicenter observational study called the IMPACT COPD Cohort China to better understand chronic obstructive pulmonary disease COPD and its common coexisting conditions. The study focuses on how COPD and these additional health problems interact and affect symptoms, flare-ups, hospital visits, and disease progression over time. The goal is to create real-world evidence to improve integrative management combining Chinese and Western medicine. Participants are observed without assigned treatments. The study combines regular clinical assessments like symptom checks, questionnaires, lung function tests, imaging, and biomarker analysis with continuous digital monitoring of heart rate, blood pressure, activity, sleep, and other physiological and behavioral factors. Traditional Chinese Medicine evaluations including tongue, pulse, and facial diagnostics also contribute to a comprehensive health profile. This approach supports the development of risk prediction models and early warning systems for COPD exacerbations and comorbidities across different care settings. During the study, participants undergo ongoing evaluations and data collection over up to 36 months. Researchers monitor the yearly rate of COPD flare-ups and the occurrence of related comorbid conditions such as hypertension, heart diseases, and diabetes. The long-term follow-up includes detailed clinical and digital health data to guide future integrated care strategies. Participation involves routine clinical visits and continuous digital monitoring to assess health status and disease progression.

Age: 40Years - 85YearsAll Genders
4 locations
S

Actively Recruiting

Researchers are conducting a multicenter, prospective observational study across 200 hospitals in China to examine current treatment patterns for chronic hepatitis B CHB. The study aims to compare patient outcomes under different treatment regimens to provide evidence-based data that can improve CHB treatment strategies and follow-up care, ultimately advancing efforts toward a functional cure for chronic hepatitis B. Participants include those receiving or planned to receive treatments such as entecavir ETV, tenofovir disoproxil fumarate TDF, tenofovir alafenamide fumarate TAF, tenofovir amibufenamide TMF, or peginterferon alpha-2b injection. The study observes real-world clinical practice without assigning treatments, capturing data on these therapies over an extended period. During the study, researchers will monitor outcomes including the percentage of patients developing HBsAg-associated hepatocellular carcinoma HCC, incidence of HCC, rates of HBsAg seroclearance and seroconversion, changes in HBsAg levels, HBV DNA levels, liver fibrosis improvement, and liver-related complications. Data collection spans from week 4 up to week 240, with continuous follow-up to assess treatment effects and patient status over time.

Age: 18Years +All Genders
162 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of Qishen Yiqi Dripping Pills in treating Chronic Heart Failure with reduced ejection fraction caused by Coronary Heart Disease, specifically in patients with Syndrome of Qi Deficiency with Blood Stasis. This phase 3 randomized controlled trial aims to provide evidence on this traditional Chinese medicine treatment for heart failure. Participants will be randomly assigned to receive either Qishen Yiqi Dripping Pills or a placebo. The treatment involves taking 2 bags of the pills orally, three times a day, half an hour after meals, over a 12-week period. The study uses a quadruple masking design to compare the effects of the active treatment with placebo. During the 12 weeks of treatment, participants will undergo various assessments including the 6-minute walk test, quality of life questionnaires, symptom tracking, echocardiographic measurements, and blood tests for heart function biomarkers at baseline and at weeks 4, 8, and 12. Researchers will monitor exercise capacity, heart failure symptoms, cardiac function, and safety throughout the study to understand the treatments impact and tolerability.

Age: 18Years - 80YearsAll GendersPhase 3
60 locations
E

Actively Recruiting

Researchers are studying patients who have had an acute ischemic stroke caused by a blockage in a large blood vessel in the brain. The trial focuses on the safety and effectiveness of remote ischemic conditioning RIC as an additional treatment to improve recovery after endovascular thrombectomy, a procedure that removes the blockage. This research addresses the challenge that even when blood flow is restored, many patients still have poor outcomes or die, possibly due to brain injury during and after the procedure. The study compares three groups one receiving only endovascular thrombectomy and best medical care, a second group receiving thrombectomy plus RIC treatment for 14 days, and a third group receiving thrombectomy plus RIC for 30 days. RIC is a noninvasive device treatment where a cuff on the upper arm inflates and deflates in cycles, applied once before thrombectomy and twice daily afterward. Best medical management follows clinical guidelines for all groups. Participants will be monitored closely for 90 days after stroke. Researchers will assess recovery using the modified Rankin Scale to measure functional independence and will record neurological improvements, brain infarct size, adverse events, and quality of life. The study includes imaging, neurological exams, and safety checks at multiple time points, including 24 hours, 14 days, 72 hours, and 90 days post-treatment to evaluate the impact of RIC on stroke outcomes.

Age: 18Years +All GendersPhase 3
56 locations
E

Actively Recruiting

Researchers are evaluating a treatment for people with spontaneous supratentorial intracerebral hemorrhage ICH, a serious type of stroke caused by bleeding in the brain. The study is a phase III randomized controlled trial that will involve 768 participants to compare a new minimally invasive surgery combined with a clot-dissolving drug against standard medical care. This trial aims to assess the safety and effectiveness of using tenecteplase to liquefy and drain brain hematomas, potentially improving recovery outcomes. Participants will be randomly assigned to one of two groups. One group will receive minimally invasive stereotactic catheter placement followed by the local injection of tenecteplase to liquefy and drain the hematoma, with doses of 0.5 mg given up to four times over several days. The other group will receive standard medical treatment in line with current guidelines. The surgery uses imaging to target the hematoma, and after catheter placement, tenecteplase is carefully administered through the catheter with close monitoring. Throughout the study, participants will undergo regular assessments including neurological exams, brain imaging, and functional outcome evaluations up to 180 days after treatment. The main measurement is the modified Rankin Score assessing disability and recovery. Other outcomes include neurological improvement, hematoma size, mortality, and quality of life. Follow-up visits may be conducted face-to-face or remotely, and researchers will carefully monitor safety and treatment effects during this period.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
51 locations